Skip to main content
Caplight Logo









Equulus Therapeutics

Equulus Therapeutics

Private
Raleigh, North CarolinaHealthcare & Life Scienceshttps://www.equulus.com/

Company Overview

Equulus Therapeutics operates in Healthcare & Life Sciences and is based in Raleigh, North Carolina. It was founded in 2023.

Equulus Therapeutics is a biotechnology company developing non-hallucinogenic, psychedelic-inspired therapeutics for central nervous system disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Mental Health

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Equulus Therapeutics Comparables

Compare Equulus Therapeutics with similar companies based on industry and business-model similarity.

Equulus Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Delix Therapeutics
85%
DemeRx, Inc.
83%
Soneira Therapeutics
81%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Equulus Therapeutics Funding Rounds

Historical fundraising activity

Funding history

No completed funding rounds are published for Equulus Therapeutics. Book a demo to ask about coverage.

Book a demo

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Robert Discordia

Co-Founder, President & CEO

Founding Team

For institutional investors. Book with your work email.

Equulus Therapeutics Filings

Explore SEC and related filing metadata, where available.

Equulus Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Equulus Therapeutics's valuation, stock price, and market status.

Is Equulus Therapeutics a public or private company?

Equulus Therapeutics is a private company.

What is the current stock price of Equulus Therapeutics?

Equulus Therapeutics is a private company, so its shares have no public market price. Caplight tracks Equulus Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Equulus Therapeutics worth (valuation)?

Valuation information for Equulus Therapeutics is not publicly available.

Can I buy Equulus Therapeutics stock?

Equulus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Equulus Therapeutics's last funding round?

Funding round information for Equulus Therapeutics is not publicly available.

Who are the main investors in Equulus Therapeutics?

Investor information for Equulus Therapeutics is not publicly disclosed.

Will Equulus Therapeutics IPO soon?

No public IPO plans have been announced for Equulus Therapeutics.

How can I track Equulus Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades in Equulus Therapeutics's shares on secondary markets.

Firmographic Details

HeadquartersRaleigh, North Carolina
Employee Range3
Year Founded2023
Last Funding—

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?